The US Food and Drug Administration (FDA) sent federal marshals to Celsus Laboratories Inc in Cincinnati on November 6 to seize the remains of 11 lots of contaminated heparin after the agency felt the company failed to take sufficient action to recall the products (http://www.fda.gov/bbs/topics/NEWS/2008/NEW01912.html).
Celsus said it had identified and quarantined suspect heparin batches following a March 6 disclosure from the FDA to the public of the potential presence of contaminated heparin imported from China containing oversulfated chondroitin sulfate (OSCS), a substance that mimics heparin's anticoagulant activity. The company said customers who had received heparin from suspect batches were informed in late March and early April (http://www.celsuslaboratories.com/news.php).
Mitka M. Contaminated Heparin Seized by FDA. JAMA. 2008;300(22):2597. doi:10.1001/jama.2008.786
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: